Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Patient characteristics, treatment patterns, and outcomes in primary CNS lymphoma of T-cell origin: A multi-institution retrospective analysis

View Full Paper
Ask AI
Bookmark
Share

Authors

OEOmar ElghawyNSNishwant SwamiFEFelix Ehret

Discussion

Loading...

Member takes

Overview

Retrospective analysis reveals prognostic factors and treatment patterns in primary CNS T-cell lymphoma, suggesting implications for clinical practice.

Key Points

  • Median overall survival was 17.6 months for patients with primary CNS T-cell lymphoma, with 62% experiencing progression.
  • The study included 42 patients aged over 18 years, indicating a significant portion had elevated LDH at diagnosis.
  • Next-generation sequencing identified disease-related mutations in TP53 and DNMT3A in 17% of cases, highlighting potential targets for therapy.
  • Findings suggest the need for standardized treatment protocols to improve patient outcomes and inform future research directions.

Cite This Study

Elghawy et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d8e4https://doi.org/10.1182/blood-2025-893
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Evaluation of treatment regimens and prognostic factors in primary central nervous system lymphomas2025 · 1 citations
  2. 2Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database2025
  3. 3When location meets biology: combined risk patterns drive outcomes in primary central nervous system lymphoma2025 · 1 citations
  4. 4Reduced Intensity Therapy for Primary Central Nervous System Post-Transplant Lymphoproliferative Disorders is Associated with Preserved Survival Outcomes: A Twenty-Year Single-Institutional Experience2025
  5. 5Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic2025